Cytokinetics, Incorporated
Cytokinetics develops muscle activators and inhibitors as potential treatments for debilitating diseases. Its drug candidates include omecamtiv mecarbil (Phase III trial), CK-136 (Phase I trial), CK-586 (Phase I trial), and aficamten (Phase III trial). The company focuses on small molecule drug candidates that impact muscle function and contractility. It has a strategic alliance with Ji Xing Pharmaceuticals Limited. Cytokinetics is headquartered in South San Francisco, California.
Overview
Strengths
- Consistent growth: revenue has compounded at 9.5% a year over 5 years, rising in 4 of them.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 6.5% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -6,590% to -168% over the last 6 years, with operating losses in 6 of them.
Key Financial Data